# A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

> **NCT06287528** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (estimated)

## Conditions studied

- Philadelphia-Negative ALL
- Philadelphia-Positive ALL
- Relapsed ALL, Adult
- Refractory Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia (ALL)
- Refractory Acute Lymphoid Leukemia in Relapse

## Interventions

- **BIOLOGICAL:** 19-28z/IL-18 CAR T cells

## Key facts

- **NCT ID:** NCT06287528
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-23
- **Primary completion:** 2028-02-23
- **Final completion:** 2028-02-23
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06287528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06287528, "A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06287528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*